Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Inclusion Criteria: * Patients whose legal representatives can provide informed consent (Informed consent from the patients where possible). * Patients who satisfy both of the following diagnostic criteria: * Diagnosis of major neurocognitive disorder due to Alzheimer's disease according to Diagnostic and Statistical Manual of mental disorders (DSM-5) * Diagnosis of probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) * Hospitalized patients or care facility patients * Patients with an Mini-Mental State Examination (MMSE) score of 1 to 22 Exclusion Criteria: * Patients with complications of dementia or memory impairment other than Alzheimer's type dementia * Dementia patients with a Modified Hachinski Ischemic Score of 5 or higher * Patients with psychological symptoms or behavioral disorders that are clearly due to other medical conditions or substances * Patients with a complication or history of stroke or transient ischemic attack, except for asymptomatic stroke * Patients with heart failure classified as New York Heart Asscoiation (NYHA） III or IV * Patients who require drug therapy for arrhythmia or ischemic heart disease * Body weight of less than 30 kg * Patients with a high risk of suicide * Patients with a complication or history of seizure disorder * Patients with a complication or history of neuroleptic malignant syndrome, tardive dyskinesia, paralytic ileus, or rhabdomyolysis * Patients with thyroid disease (except if the disease has been stabilized with drug therapy for 3 months or longer prior to time of informed consent)